[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60009315D1 - Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung - Google Patents

Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Info

Publication number
DE60009315D1
DE60009315D1 DE60009315T DE60009315T DE60009315D1 DE 60009315 D1 DE60009315 D1 DE 60009315D1 DE 60009315 T DE60009315 T DE 60009315T DE 60009315 T DE60009315 T DE 60009315T DE 60009315 D1 DE60009315 D1 DE 60009315D1
Authority
DE
Germany
Prior art keywords
treatment
dewanning
cyamemazine
symptoms
benzodiazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009315T
Other languages
English (en)
Other versions
DE60009315T2 (de
Inventor
Alche-Biree Francoise D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE60009315D1 publication Critical patent/DE60009315D1/de
Application granted granted Critical
Publication of DE60009315T2 publication Critical patent/DE60009315T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60009315T 1999-08-13 2000-07-28 Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung Expired - Lifetime DE60009315T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9910472A FR2797399B1 (fr) 1999-08-13 1999-08-13 Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
FR9910472 1999-08-13
PCT/FR2000/002186 WO2001012265A1 (fr) 1999-08-13 2000-07-28 Utilisation de la cyamemazine dans le traitement du sevrage brutal aux benzodiazepines

Publications (2)

Publication Number Publication Date
DE60009315D1 true DE60009315D1 (de) 2004-05-13
DE60009315T2 DE60009315T2 (de) 2005-02-17

Family

ID=9549128

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009315T Expired - Lifetime DE60009315T2 (de) 1999-08-13 2000-07-28 Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Country Status (12)

Country Link
US (1) US6534500B2 (de)
EP (1) EP1212119B1 (de)
JP (1) JP5078209B2 (de)
AT (1) ATE262362T1 (de)
AU (1) AU6846300A (de)
CA (1) CA2381354C (de)
DE (1) DE60009315T2 (de)
DK (1) DK1212119T3 (de)
ES (1) ES2214305T3 (de)
FR (1) FR2797399B1 (de)
PT (1) PT1212119E (de)
WO (1) WO2001012265A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626727B1 (de) * 2003-02-07 2008-12-31 Aventis Pharmaceuticals Inc. Verwendung von 2-cyano-10- (2-methyl-3- (methylamino)- propyl)-phenothiazin oder einem pharmazeutisch akzeptablen salz davon als arzneimittel
FR2850871B1 (fr) * 2003-02-07 2006-07-14 Aventis Pharma Sa Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament
US7855196B2 (en) * 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
DE102011078999A1 (de) 2011-07-12 2013-01-17 Carl Zeiss Sms Gmbh Verfahren und Vorrichtung zur Positionsbestimmung von Strukturen auf einer Maske für die Mikrolithographie
DE102013101445B9 (de) 2013-02-14 2022-01-05 Carl Zeiss Smt Gmbh Verfahren zur Ermittlung von Verzeichnungseigenschaften eines optischen Systems in einer Messvorrichtung für die Mikrolithographie
DE102013106320B9 (de) 2013-06-18 2021-07-01 Carl Zeiss Smt Gmbh Verfahren zur Ermittlung von Verzeichnungseigenschaften eines optischen Systems in einer Messvorrichtung für die Mikrolithographie
DE102013107976B4 (de) 2013-07-25 2016-07-28 Carl Zeiss Sms Gmbh Positionsbestimmung von Strukturen auf einer Maske für die Mikrolithographie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE552557A (de) * 1955-11-15
US4666903A (en) * 1985-08-13 1987-05-19 Yale University Novel use of benzodiazepine antagonist
FR2654621B1 (fr) 1989-11-22 1994-09-23 Esteve Labor Dr Inhibition du syndrome d'abstinence.
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
JP2001517223A (ja) 1997-04-02 2001-10-02 バイオニケ ライフ サイエンシーズ インコーポレイテッド 原生動物性または寄生生物性疾患の予防、治療または排除のための細菌細胞壁抽出物の使用

Also Published As

Publication number Publication date
ES2214305T3 (es) 2004-09-16
US6534500B2 (en) 2003-03-18
PT1212119E (pt) 2004-07-30
WO2001012265A1 (fr) 2001-02-22
JP2003507352A (ja) 2003-02-25
CA2381354A1 (fr) 2001-02-22
CA2381354C (en) 2008-12-30
AU6846300A (en) 2001-03-13
JP5078209B2 (ja) 2012-11-21
FR2797399A1 (fr) 2001-02-16
US20020183332A1 (en) 2002-12-05
DK1212119T3 (da) 2004-06-21
EP1212119A1 (de) 2002-06-12
FR2797399B1 (fr) 2002-10-18
ATE262362T1 (de) 2004-04-15
DE60009315T2 (de) 2005-02-17
EP1212119B1 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
BR0011130A (pt) Inibidores de metaloproteases
ATE340171T1 (de) Piperazinderivate zur behandlung bakterieller infektionen
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
SE9802208D0 (sv) Novel compounds
ATE271865T1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
UY26426A1 (es) Nuevos compuestos
SE9902267D0 (sv) New compounds
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
TR200200278T2 (tr) Kalsilitik bileşimler
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE50010972D1 (de) UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC